Pharmacokinetics of BIBR 277 in Hypertensive Patients

Exclusion Criteria

• •Malignant hypertension
• •Renovascular hypertension
• •Severe heart failure (NYHA functional class III - IV), unstable angina pectoris, or history of myocardial infarction (within 6 months of onset)
• •Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
• •Symptoms of cerebrovascular disorder
• •Serious hepatic dysfunction
• •Renal function disorder (serum creatinine \>= 4.0 mg/dL)
• •Known hypersensitivity to angiotensin II receptor antagonists
• •Hyperkalaemia (potassium \>= 5.5 milliequivalents per liter (mEq/L))
• •Treatment with the other investigational drug within 6 months of initiation of the present study
• •Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
• •Previous treatment with the trial medication of the present study
• •Otherwise judged ineligible by the investigator